NEW YORK--(BUSINESS WIRE)--

Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, today announced that it has filed a class action against OvaScience, Inc. (“OvaScience” or the “Company”) (NASDAQ:OVAS) and certain of its senior executives and directors (collectively, “Defendants”).

The action, which is filed in the U.S. District Court for the District of Massachusetts, asserts claims under Sections 11, 12(a), and 15 of the Securities Act of 1933 (the “Securities Act”), on behalf of investors who purchased OvaScience common stock directly in the Company’s January 8, 2015 Secondary Offering and who were damaged thereby (the “Class”).

OvaScience is a life science company that engages in the discovery, development, and commercialization of new treatments for infertility. The Company is attempting to develop various fertility treatment options purported to enhance egg health and revolutionize in vitro fertilization (“IVF”). The Company’s Autologous Germline Mitochondrial Energy Transfer (“AUGMENT”) treatment, designed to improve the energy and health of the woman’s eggs by using mitochondria from a woman’s egg precursor cells (“EggPCs”), is available in certain IVF clinics in select international regions.

According to the complaint, Defendants violated provisions of the Securities Act by issuing false and misleading statements to investors, including in filings with the U.S. Securities and Exchange Commission (“SEC”). Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the very science behind AUGMENT was untested and in doubt; (2) the patients that had received OvaScience’s AUGMENT procedure in 2014 did not achieve a pregnancy success rate that was significantly higher than the rate achieved without the Company’s AUGMENT procedure; (3) the Company had not chosen to undertake its studies outside of the United States, but was forced to as it did not want to meet stringent and expensive federal regulations; and (4) the Company was far from being profitable, or even approaching profitability.

If you wish to serve as lead plaintiff, you must move the Court no later than January 22, 2018. Any member of the proposed class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain a member of the proposed class.

If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Rhiana Swartz of Scott+Scott at (844) 818-6980, or via email at [email protected].

About Scott+Scott, Attorneys at Law, LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171122005613/en/